Loading...
•
Mar 31, 2023
Applied Therapeutics Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Applied Therapeutics reported its Q1 2023 financial results, highlighting the long-term clinical benefit of Govorestat in the ACTION-Galactosemia Kids Trial and a strengthened balance sheet with a $30 million private placement of equity. Phase 3 INSPIRE trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy are on track for data in 2023.
Demonstrated long-term clinical benefit of Govorestat in ACTION-Galactosemia Kids Trial.
Strengthened balance sheet with $30 million private placement of equity.
Phase 3 INSPIRE Trial of Govorestat in SORD Deficiency on track for data in 2023.
ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on track for data in 2023.
Applied Therapeutics
Applied Therapeutics
Forward Guidance
The company anticipates potential approval of govorestat for Galactosemia later this year and is excited about upcoming data readouts in SORD Deficiency and Diabetic Cardiomyopathy.